Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 2
1977 2
1979 2
1981 3
1982 3
1983 2
1984 13
1985 11
1986 13
1987 18
1988 15
1989 12
1990 15
1991 23
1992 14
1993 7
1994 16
1995 18
1996 14
1997 30
1998 10
1999 16
2000 36
2001 18
2002 26
2003 28
2004 27
2005 25
2006 24
2007 27
2008 35
2009 37
2010 38
2011 37
2012 30
2013 38
2014 48
2015 39
2016 26
2017 35
2018 29
2019 15
2020 21
2021 13
2022 8
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

883 results

Results by year

Filters applied: . Clear all
Page 1
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A. Orkin C, et al. Among authors: lazzarin a. AIDS. 2024 Jun 1;38(7):983-991. doi: 10.1097/QAD.0000000000003865. Epub 2024 Feb 21. AIDS. 2024. PMID: 38349226 Free PMC article. Clinical Trial.
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. Liver Int. 2024. PMID: 38100128 Free article.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G, Lazzarin A, Santoni M, Trentini F, Giorgi U, Brighi N, Tommasi C, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Silini EM, Rescigno P, Rebuzzi SE, Fornarini G, Quaini F, Giudice GC, Banna GL, Buti S. Mazzaschi G, et al. Among authors: lazzarin a. Front Biosci (Elite Ed). 2023 Jul 28;15(3):20. doi: 10.31083/j.fbe1503020. Front Biosci (Elite Ed). 2023. PMID: 37743233 Free article.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.
Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D; GS-US-380-1489 and GS-US-380-1490 study investigators. Sax PE, et al. Among authors: lazzarin a. EClinicalMedicine. 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37200995 Free PMC article.
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Álvarez H, et al. Clin Infect Dis. 2023 Aug 22;77(4):593-605. doi: 10.1093/cid/ciad219. Clin Infect Dis. 2023. PMID: 37052343 Free PMC article.
883 results